WASHINGTON--Laboratory studies from Rockefeller University, presented at Digestive Disease Week, suggest that caffeine(Drug information on caffeine) may have a synergistic effect with NSAIDs in preventing the growth of cancer cells.
At a press briefing, Yael Goldberg, MD, said that laboratory tests have shown that NSAIDs have an antiproliferative effect on colon cancer cells as well as the capacity to interfere with the cell cycle and induce apoptosis. And among the cells that do not die, about 90% arrest in the cell cycle, she said.
Working in the laboratory of Dr. Steven Shiff, Dr. Goldberg and her colleagues treated colon cancer cells with different agents in an attempt, she said, "to look more closely at the mechanism responsible for the antineoplastic effect of NSAIDs, and to think about practical ways to treat patients."
The researcher treated HT-29 colon adenocarcinoma cells and U-2 OS osteosarcoma cells for 72 hours with either a control medium alone or a control medium supplemented with indomethacin (400 µM), sulindac(Drug information on sulindac) (1,200 µM), sulindac sulfide (175 µM), or caffeine (4 µM), or co-supplemented with caffeine and one of each of the NSAIDs.
In both HT-29 and U-2 OS cells, caffeine treatment alone profoundly inhibited proliferation but did not induce apoptosis.
Co-treatment with caffeine and one of the NSAIDs reduced proliferation more than did treatment with any of the agents used alone. When used in combination, caffeine significantly enhanced NSAID-induced apoptosis, and also altered cell cycle distribution and levels of several key proteins that likely modulate the NSAID-induced cell cycle arrest.